Accueil Ernstrade Bourse Actualite Stock


Exchanges: Frankfurt

Paion AG is a Germany-based pharmaceutical holding company. It develops and commercializes drugs for the treatment of strokes and problems relating to the central nervous system, as well as other thrombotic and cardiovascular diseases. Paion AG's core activity is the advancement of drug candidates, both purchased and licensed in-house, through the clinical development phases and regulatory approval process. The Company has several products, including Desmoteplase, a blood clot-dissolving plasminogen activator for treating acute ischemic strokes, which finished the Phase III stage of clinical trials; CNS 7056, a short-acting sedative and general anaesthetic (Phase II), and Solulin, a thrombin modulator for the treatment of cardiovascular disease and radiation injury (Phase I), among others. Paion AG operates worldwide through partnership with H. Lundbeck A/S. In June 2008, the Company acquired CeNeS Pharmaceuticals PLC alongside its subsidiaries and renamed it Paion Holdings UK Ltd.

Copyright  2009